Hs 445 (ATCC® HTB-146)

Organism: Homo sapiens, human  /  Disease: Hodgkin's disease; Hodgkin's lymphoma

Organism Homo sapiens, human
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells Contain HERPESVIRUS

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Hodgkin's disease; Hodgkin's lymphoma
Age 56 years
Gender female
Ethnicity Caucasian
Applications
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
0.3% to 0.5% of the cells are positive for EBV early antigen and virion antigen by immunofluorescence.
Derivation
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
Clinical Data
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
female
Caucasian
56 years
Tumorigenic Yes
Effects
Yes, in X-irradiated or anti lymphocyte serum treated nude mice
No, in anti thymocyte serum treated Swiss mice
Comments
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
By electron microscopy, herpesvirus-like particles have been seen.
0.3% to 0.5% of the cells are positive for EBV early antigen and virion antigen by immunofluorescence.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Establish new cultures at 4 X 10 exp5 cells/ml and maintain at between 4 X 10 exp5 and 1 X 10 exp6 cells/ml.
Cryopreservation
Culture medium, 95%; DMSO, 5%
STR Profile
Amelogenin: X
CSF1PO: 11,10.3
D13S317: 11,13
D16S539: 9,11
D5S818: 9,12
D7S820: 9,10
THO1: 6,7
TPOX: 8
vWA: 14,17
Isoenzymes
ES-D, 1
G6PD, B
GLO-I, 1-2
PGM1, 1
Name of Depositor RB Owens
References

Arnstein P, et al. Propagation of human tumors in antithymocyte serum-treated mice. J. Natl. Cancer Inst. 52: 71-84, 1974. PubMed: 4544026

Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523

Basic Documentation
References

Arnstein P, et al. Propagation of human tumors in antithymocyte serum-treated mice. J. Natl. Cancer Inst. 52: 71-84, 1974. PubMed: 4544026

Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523